BNP-45 rat (Brain natriuretic peptide-45 rat) |
| رقم الكتالوجGC32612 |
فأر BNP-45 (جرذ ببتيد ناتريوتريك للدماغ -45 جرذ) (BNP-45 ، جرذ) هو شكل متداول من الببتيد الناتريوتريك في دماغ الجرذ المعزول من قلب الجرذان مع قوة فعالة خافضة للضغط ومغذية للصوديوم.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 123337-89-3
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
BNP-45 (rat), a 45-amino acid brain natriurctic peptide isolated from rat heart, is a circulating hormone, with natriuretic andhypotensive activities.
BNP-45 (rat), a 45-amino acid brain natriurctic peptide isolated from rat heart, is a circulating hormone, with natriuretic andhypotensive activities[1].
BNP-45 (rat) (0.1, O.2, 0.5, 1.0 and 2.0 nmol/kg, i.v.) shows potent natriuretic and hypotensive activities in anesthetized spontaneously hypertensive rats (SHR) and Wistar-Kyoto rats (WKY). BNP-45 (rat) with high concentration decreases blood pressure in SHR. But WKY is more susceptible than SHR to BNP-45 for diuresis, natriuresis and urinary cGMP excretion. In addition, high dose of BNP-45 (rat) cuases prolonged lowering of blood pressure and urinary cGMP excretion in WKY[1].
[1]. Kita T, et al. Effects of brain natriuretic peptide-45, a circulating form of rat brain natriuretic peptide, in spontaneously hypertensive rats. Eur J Pharmacol. 1991 Sep 4;202(1):73-9.
Animal experiment: | Rats[1]Male anesthetized spontaneously hypertensive rats (SHR) and Wistar-Kyoto rats (WKY) (20- to 25 week-old) are used in the assay. Isotonic saline (20 μL/min) is infused throughout the esperiment. After equilibration for at least 60 min, urine is collected every 10 min during a 20-min control period. Rat BNP-45 or rat α-ANP (0.1, O.2, 0.5, 1.0 and 2.0 nmol/kg) dissolved in saline containing 1% bacitracin is injected i.v., and urine is collected continuously for three to six 10-min periods following each dose. There is a 30- to 60-min rest interval between each injection, to allow the urine volume to return to a steady baseline value. Urine volume is determined by weight. Urinary sodium and potassium are measured by flame photometry. The concentration of cGMP in urine is measured by radioimmunoassay, using cGMP assay kit[1]. |
References: [1]. Kita T, et al. Effects of brain natriuretic peptide-45, a circulating form of rat brain natriuretic peptide, in spontaneously hypertensive rats. Eur J Pharmacol. 1991 Sep 4;202(1):73-9. | |
| Cas No. | 123337-89-3 | SDF | |
| Canonical SMILES | Ser-Gln-Asp-Ser-Ala-Phe-Arg-Ile-Gln-Glu-Arg-Leu-Arg-Asn-Ser-Lys-Met-Ala-His-Ser-Ser-Ser-Cys-Phe-Gly-Gln-Lys-Ile-Asp-Arg-Ile-Gly-Ala-Val-Ser-Arg-Leu-Gly-Cys-Asp-Gly-Leu-Arg-Leu-Phe(Disulfide bridge: Cys23-Cys39) | ||
| Formula | C213H349N71O65S3 | M.Wt | 5040.67 |
| الذوبان | Soluble in Water | Storage | Store at -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 198.4 μL | 991.9 μL | 1.9839 mL |
| 5 mM | 39.7 μL | 198.4 μL | 396.8 μL |
| 10 mM | 19.8 μL | 99.2 μL | 198.4 μL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 27 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *